Glassman Wealth Services reduced its position in Celgene Co. (NASDAQ:CELG) by 2.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,520 shares of the biopharmaceutical company’s stock after selling 58 shares during the period. Glassman Wealth Services’ holdings in Celgene were worth $292,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of CELG. First Financial Corp IN increased its stake in shares of Celgene by 30.9% in the third quarter. First Financial Corp IN now owns 967 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 228 shares during the last quarter. Barnett & Company Inc. increased its stake in shares of Celgene by 18.3% in the third quarter. Barnett & Company Inc. now owns 1,130 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 175 shares during the last quarter. Jolley Asset Management LLC increased its stake in shares of Celgene by 2.1% in the third quarter. Jolley Asset Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 25 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in shares of Celgene during the fourth quarter worth about $146,000. Finally, Smithfield Trust Co. increased its stake in shares of Celgene by 2.2% in the third quarter. Smithfield Trust Co. now owns 1,310 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 28 shares during the last quarter. 77.68% of the stock is owned by institutional investors and hedge funds.
Shares of Celgene Co. (NASDAQ:CELG) traded down 0.82% during midday trading on Friday, reaching $122.26. 2,913,961 shares of the company’s stock traded hands. Celgene Co. has a one year low of $94.42 and a one year high of $127.64. The company has a market capitalization of $95.11 billion, a price-to-earnings ratio of 49.10 and a beta of 1.74. The company has a 50-day moving average of $124.35 and a 200-day moving average of $116.46.
TRADEMARK VIOLATION NOTICE: This story was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://transcriptdaily.com/2017/04/22/glassman-wealth-services-has-292000-stake-in-celgene-co-celg.html.
A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald set a $159.00 price objective on shares of Celgene and gave the stock a “buy” rating in a research report on Saturday, February 18th. Jefferies Group LLC reiterated a “buy” rating and issued a $154.00 target price on shares of Celgene in a research note on Tuesday, April 11th. Zacks Investment Research cut shares of Celgene from a “buy” rating to a “hold” rating in a research note on Wednesday, December 28th. Cowen and Company reiterated an “outperform” rating and issued a $150.00 target price on shares of Celgene in a research note on Wednesday, March 8th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $162.00 target price on shares of Celgene in a research note on Wednesday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-four have issued a buy rating to the company’s stock. Celgene has an average rating of “Buy” and a consensus price target of $139.46.
In other news, Director Gilla Kaplan sold 14,033 shares of Celgene stock in a transaction on Thursday, March 30th. The stock was sold at an average price of $123.83, for a total transaction of $1,737,706.39. Following the transaction, the director now owns 73,109 shares in the company, valued at approximately $9,053,087.47. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Rupert Vessey sold 4,000 shares of Celgene stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $124.42, for a total value of $497,680.00. Following the transaction, the insider now owns 778 shares in the company, valued at approximately $96,798.76. The disclosure for this sale can be found here. Company insiders own 0.97% of the company’s stock.
About Celgene
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
